B. Riley Securities to Host Mind, Muscle & Vision Healthcare Summit on July 16, 2026

Rhea-AI Summary

B. Riley Securities (NASDAQ:RILY) will host its Mind, Muscle & Vision Healthcare Summit on July 16, 2026, in Boston.

The single-day, invitation-only event links institutional investors with healthcare companies in psychiatry, neurology, neuromuscular, cardiology and ophthalmology across three tracks: Mind, Muscle and Vision.

News Market Reaction – RILY

-7.43%

8 alerts

-7.43% Session close to close

$339.01M Market Cap

0.4x Rel. Volume

In the Jun 5 session, RILY declined 7.43%, reflecting a notable negative market reaction. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -7.4% in the session following this news. A negative reaction despite a neutral conf...

Analysis

The stock moved -7.4% in the session following this news. A negative reaction despite a neutral conference announcement would fit a pattern where RILY often traded lower around positive or constructive updates, including strong earnings. With short interest at 16.65% and several prior divergences between fundamentals and price, downside moves could be amplified by positioning. Future behavior around concrete financial or regulatory milestones may be more telling than reaction to event branding alone.

Key Figures

Conference date: July 16, 2026 Strategic capital: $30 billion Deal share: 25% +1 more

4 metrics

Conference date July 16, 2026 Mind, Muscle & Vision Summit event date in Boston

Strategic capital $30 billion YTD 2026 pharma commitments to CNS, muscle, ophthalmology programs

Deal share 25% Portion of total 2026 deal activity by size and volume in these areas

Catalyst horizon 2027 Timeline for expected commercial, clinical trial, and regulatory catalysts

Historical Context

5 past events · Latest: Jun 03 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 03	Specialty finance deal	Positive	-2.8%	Assumed $20M advance under $100M term loan for AI data center financing.
May 19	Leadership additions	Positive	+0.0%	Return of senior executives to drive capital markets and investment banking growth.
May 07	Q1 2026 earnings	Positive	-5.9%	Strong Q1 results with $211.3M net income and debt reduction initiatives.
Apr 30	Earnings call notice	Neutral	+13.6%	Announcement of Q1 2026 earnings call and replay availability dates.
Apr 29	FY25 earnings	Positive	-1.3%	FY25 results with $260.2M revenue, $69.9M net income and $42B raised.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows multiple instances where seemingly positive corporate or financial updates coincided with flat or negative price reactions, suggesting a tendency for the stock to underreact or sell off on good news.

Recent Company History

Over the last few months, RILY has reported strong financial results and strategic actions. On Apr 29, FY25 results highlighted $260.2M revenue and $69.9M net income, yet shares fell. The May 7 Q1 2026 report showed robust net income and deleveraging, again followed by a decline. Leadership additions on May 19 had little price impact. The June loan and financing activity on Jun 3 also coincided with weakness. Against this backdrop, the Mind, Muscle & Vision Summit announcement continues a pattern of active corporate development alongside mixed market reactions.

Key Terms

cns, ophthalmology, lysosomal storage disorders, neuromuscular, +3 more

7 terms

cns medical

"pharma strategics have committed over $30 billion to CNS, muscle, and ophthalmology programs"

CNS stands for the central nervous system, the brain and spinal cord that control thought, movement and bodily functions. For investors, CNS-focused products and research matter because therapies aimed at this “delicate wiring” are scientifically challenging, often carry higher development and regulatory risk, and can take longer to prove safe and effective — but successful treatments also tend to command large markets and premium pricing.

ophthalmology medical

"committed over $30 billion to CNS, muscle, and ophthalmology programs"

Ophthalmology is the branch of medicine that diagnoses, treats and prevents eye diseases and vision problems, ranging from routine exams to surgery. For investors, it matters because advances, approvals or setbacks in eye drugs, surgical tools, diagnostics or implants can change sales, regulatory risk and long-term demand—think of it as the medical ‘repair and upgrade’ market for a vital organ.

lysosomal storage disorders medical

"next-generation brain delivery, and lysosomal storage disorders."

A group of inherited conditions where cells cannot break down and clear certain molecules, like a clogged recycling center inside cells causing harmful buildup that damages organs and the nervous system. Investors care because these disorders create clear targets for specialized treatments, often qualify for orphan-drug incentives and accelerated review, and can drive focused clinical programs and high-value niche markets if therapies prove safe and effective.

neuromuscular medical

"sponsors developing cutting-edge therapies for rare neuromuscular, cardiology and inflammatory"

Relating to the connection and interaction between nerves and muscles, neuromuscular describes how signals from the nervous system make muscles move and function. For investors, neuromuscular issues and treatments matter because they drive demand for drugs, devices and diagnostic tests, shape development timelines and regulatory risks, and can change long-term revenue prospects in healthcare—think of it like the wiring and motors in a machine where problems or fixes affect overall performance and value.

inflammatory indications medical

"therapies for rare neuromuscular, cardiology and inflammatory indications."

Conditions or diseases where the body's immune response causes redness, swelling, pain or tissue damage—examples include arthritis, inflammatory bowel disease and certain skin disorders. Investors care because medicines or tests targeting these conditions can address large, chronic patient populations and create steady revenue streams; success or failure in clinical trials, approvals or reimbursement decisions for such treatments often has a direct impact on a healthcare company's market value.

clinical trial medical

"many poised for meaningful commercial, clinical trial, and regulatory catalysts into 2027."

A clinical trial is a carefully controlled study in which a new medicine, medical device, or treatment is tested on people to see if it is safe and effective. For investors it matters because trial results determine whether a product can win regulatory approval and reach patients, much like a road test decides if a new car can be sold; positive or negative results can sharply change a company’s prospects and stock value.

regulatory catalysts regulatory

"meaningful commercial, clinical trial, and regulatory catalysts into 2027."

Regulatory catalysts are official actions or milestones from government agencies or regulators—such as approvals, clearances, rule changes or safety reviews—that can suddenly change a company’s prospects. They matter to investors because these decisions can act like traffic signals for a business, either clearing the way for sales and growth or creating delays and added costs, and often trigger sharp moves in a stock’s value as market expectations are updated.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, June 4, 2026 /PRNewswire/ -- B. Riley Securities, Inc. ("B. Riley Securities"), a leading full-service investment bank, today announced it will host the Mind, Muscle & Vision Summit – a premier single-day healthcare conference connecting institutional investors with management teams pioneering cutting-edge innovations in neurology, muscle and eyecare disease states. The event will take place on Thursday, July 16, 2026, in Boston, MA.

Participating companies are selected by B. Riley Securities' award-winning equity research team, ensuring investors access to differentiated opportunities across psychiatry, neurology, neuromuscular, cardiology, and ophthalmology – many poised for meaningful commercial, clinical trial, and regulatory catalysts into 2027.

The summit will feature research analyst-hosted thematic industry panel discussions, one-on-one and small group meetings with corporate management teams and institutional investors across three dedicated tracks:

• Mind Track: Featuring innovators focused on psychiatry, neurology, neurodegeneration, next-generation brain delivery, and lysosomal storage disorders.
• Muscle Track: Encompassing sponsors developing cutting-edge therapies for rare neuromuscular, cardiology and inflammatory indications.
• Vision Track: Highlighting innovative biotechs targeting both front- and back-of-the-eye conditions.

B. Riley Securities' Mind, Muscle & Vision Summit comes at a highly dynamic time for this fast-growing sub-sector. Year-to-date in 2026, pharma strategics have committed over $30 billion to CNS, muscle, and ophthalmology programs - roughly 25% of total deal activity by size and volume. These exits represent a durable, accelerating trend that has returned significant capital to industry-dedicated investors now actively seeking their next opportunities.

"Our equity research team has a strong record of identifying differentiated healthcare companies ahead of the broader market, and this summit reflects that discipline. We're bringing together institutional investors with management teams across high-value therapeutic verticals at a moment when strategic capital is accelerating and meaningful commercial, clinical and regulatory milestones are on the horizon," said Andy Moore, CEO, B. Riley Securities.

Institutional investors and industry professionals interested in attending, scheduling one-on-one meetings, or learning more about the participating companies are encouraged to register early.

Participation is by invitation only. To request an invitation, contact your B. Riley Securities representative or email healthcareevents@brileysecurities.com. For sponsorship inquiries, email conference@brileysecurities.com.

About B. Riley Securities, Inc.
B. Riley Securities, Inc. provides a full suite of investment banking and capital markets services to corporations, financial sponsors, and institutional investors across all industry verticals. Services include initial and follow-on offerings, debt and equity-linked solutions, institutional private placements, merger and acquisition (M&A) advisory, corporate restructuring, and liability management. Widely recognized for its thematic proprietary equity research, B. Riley Securities offers clients an extensive network, deep industry expertise, and proven execution capabilities through its end-to-end platform. For more information, visit www.brileysecurities.com and follow us on LinkedIn.

Media Contact:
Jo Anne McCusker
B. Riley Securities
press@brileysecurities.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/b-riley-securities-to-host-mind-muscle--vision-healthcare-summit-on-july-16-2026-302791996.html

SOURCE B. Riley Securities

FAQ

What is the Mind, Muscle & Vision Healthcare Summit hosted by B. Riley Securities (RILY)?

The Mind, Muscle & Vision Summit is a single-day healthcare conference linking institutional investors with management teams in CNS, muscle and ophthalmology. According to B. Riley Securities, it focuses on commercial, clinical trial and regulatory catalysts across psychiatry, neurology, neuromuscular, cardiology and ophthalmology.

When and where will B. Riley Securities (RILY) hold the Mind, Muscle & Vision Summit 2026?

The Mind, Muscle & Vision Healthcare Summit will take place on July 16, 2026, in Boston, Massachusetts. According to B. Riley Securities, the event is a single-day, in-person conference featuring panels, one-on-one meetings and three dedicated tracks: Mind, Muscle and Vision.

Who can attend the B. Riley Securities (RILY) Mind, Muscle & Vision Summit and how do they register?

Attendance at the Mind, Muscle & Vision Summit is by invitation only for institutional investors and industry professionals. According to B. Riley Securities, interested parties should contact their firm representative or email the listed healthcare events address to request an invitation and schedule meetings.

What investor opportunities will be highlighted at the B. Riley Securities (RILY) Mind, Muscle & Vision Summit 2026?

The summit will highlight companies in psychiatry, neurology, neuromuscular, cardiology and ophthalmology with upcoming catalysts. According to B. Riley Securities, pharma has committed over $30 billion to these areas in 2026, representing roughly 25% of total deal activity by size and volume.

What are the Mind, Muscle and Vision tracks at the B. Riley Securities (RILY) healthcare summit?

The Mind track covers psychiatry, neurology, neurodegeneration, brain delivery and lysosomal storage disorders. According to B. Riley Securities, the Muscle track focuses on rare neuromuscular, cardiology and inflammatory indications, while the Vision track features biotechs targeting front- and back-of-the-eye conditions.

How does B. Riley Securities (RILY) select companies for the Mind, Muscle & Vision Healthcare Summit?

Participating companies are selected by B. Riley Securities’ equity research team based on their healthcare coverage universe. According to the firm, this aims to provide institutional investors access to differentiated opportunities positioned for commercial, clinical trial and regulatory milestones into 2027.